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LEVEL OF EVIDENCE: 1B
SUMMARY
Background. This placebo-controlled, double-blind study evaluated the short-term effects of beta-
methasone valerate (BMV) 2.25mg medicated plaster in patients with chronic lateral elbow tend-
inopathy (LET).
Methods. Adult outpatients with LET and on-movement pain intensity ≥50 mm at a 0-100mm 
visual analogue scale (VAS) were randomised to receive BMV (N=101) or placebo (N=98), 12 
hours/day for 4 weeks. Pain decrease from baseline to Day 28 was the primary endpoint. Other 
endpoints were: patient-rated tennis elbow evaluation (PRTEE), use of rescue paracetamol, toler-
ability at the application site.
Results. Decrease in mean pain VAS from baseline to Day 28 was significantly higher with BMV 
vs. placebo: the difference between groups (intent-to-treat) was -8.57 mm (95% CI: -16.19 to 
-0.95 mm; p=0.028). Higher pain decreases in the BMV group over placebo were reported week-
ly during each control visit and daily in patients’ measurements on diaries. Treatment with BMV 
also led to higher decreases vs. placebo in PRTEE total, pain and functional disability score. Use 
of paracetamol was minimal. BMV plaster was well tolerated for general and local adverse events.
Conclusions. BMV 2.25mg plaster was superior to placebo and well tolerated in patients with pain-
ful chronic LET. 
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BACKGROUND
Primary disorders of tendons are common and account 
for a high proportion of referrals to rheumatologists and 
orthopaedic surgeons (1). The current evidence suggests 
that several proinflammatory agents may play a role in the 
development of tendon disorders, which include cytokines, 
proteolytic enzymes, growth factors and neuropeptides (2). 
However inflammation and degenerative changes often 
coexist in the course of tendon disorders and their relative 
contributions are difficult to dissect (3). 
Lateral elbow tendinopathy (LET), or “tennis elbow,” is a 
common painful musculo-tendinous degenerative disorder 
at the lateral humeral epicondyle, which is likely caused by 
repetitive occupational or athletic activities involving wrist 
extension and supination (4). LET affects middle-aged men 
and women in similar rate, and it is estimated that approxi-
mately 40% of people will experience this condition, with a 
reported point prevalence of up to 3% in the general popu-
lation (5). 
Corticosteroid injections are widely used for LET treatment 
and strong evidence suggests that they are beneficial in the 
short term for treatment of tendinopathy (6) but injection 
into the tendon might weaken its structure and increase 
probability of rupture, and cause other minor complications 
such as post-injection pain and subcutaneous atrophy (7, 8). 
Thus, the development of topical formulation of corticoste-
roids, which can maintain efficacy while minimizing adverse 
effects and discomfort due to intra-articular injection, might 
represent a therapeutic advance in the treatment of symp-
tomatic tendinopathies. Studies using topically-applied 
steroids treatment have demonstrated their efficacy as pain 
reliever in tendon disorders (9, 10), including LET (11). 
Among the currently available topical corticosteroids, beta-
methasone valerate (BMV) is largely used for the treatment 
of severe inflammatory disorders. IBSA Institut Biochimique 
S.A. has developed a medicated plaster containing 2.25 of 
BMV at a 0.1% concentration of the corticosteroid in the 
adhesive layer. This BMV medicated plaster is marketed in 
several European countries in the treatment of inflammato-
ry skin disorders which do not respond to treatment with 
less potent corticosteroids, such as eczema and psoriasis, 
lichenification, lichen planus, granuloma annulare, palmo-
plantar pustulosis and mycosis fungoides (12). 
In a phase II, placebo-controlled study (13), 102 patients 
with chronic LET and chronic Achilles tendinopathy were 
randomised to receive two different dose regimens (i.e., 12 
or 24 hours of application/day) of BMV 2.25 mg medicated 
plaster over a maximum period of 4 weeks. The active plaster 
was effective and superior to placebo in pain relief, without 
significant difference between the two treatment regimens. 
Based on the findings of the Phase II study and taking 
into consideration a trend toward a better local tolerabil-
ity observed with the use of the 12-hour application, this 
regimen has been considered as the most appropriate for 
further development. LET has been chosen as the elective 
indication due to its higher prevalence compared to the 
other type of symptomatic tendinopathy (e.g. Achilles tend-
inopathy), which was also included and positively assessed 
in the phase II study. 
The objective of this study was to evaluate the short-term 
efficacy of BMV 2.25 mg medicated plaster applied 12 
hours/day for 4 weeks, as compared to placebo plaster, 
in reducing pain and functional disability in patients with 
chronic LET.
MATERIALS AND METHODS
The study population included outpatients of either sex 
aged ≥ 18 years with chronic (i.e. for ≥12 weeks) symptom-
atic lateral elbow tendinopathy. To be eligible for study 
participation, patients were required to have a pain inten-
sity ≥ 50 mm on a 0-100 mm Visual Analogue Scale (VAS) 
as perceived on a standardized movement (according to 
Cozen’s or Mill’s test).
Patients with any of the following conditions were exclud-
ed from the study: use of non-steroidal anti-inflammatory 
drugs (NSAIDs), opioids or narcotic analgesics in the last 7 
days; local injections of corticosteroids for the tendinopathy 
in the last 6 months or for any other conditions in the last 
months; use of systemic corticosteroids in the last month; 
use of physiotherapy (except for cold or hot patch appli-
cation and/or use of braces for casting), electro-medical 
Tecar therapy, laser therapy or iontophoresis in the last 3 
months; history of fractures or ruptures of tendon or surgi-
cal treatment in the affected area; presence of skin lesions or 
dermatological diseases in the affected area that could inter-
fere with the application of the plaster; history of musculo-
skeletal, neurological disorders or other  systemic diseases 
potentially affecting the outcome of the study; pregnancy or 
breast-feeding. 
The study was conducted according to a phase III, random-
ized, double blind, parallel-group, placebo-controlled 
design. The study plan included a screening/randomisa-
tion visit (Day 1), three follow-up visits on a weekly basis 
(Days 4, 14 and 21) and a final visit at Day 28. Visits were 
performed in the morning at approximately the same time 
of the day. 
Eligible patients were randomised to receive 2.25 mg of 
BMV medicated plaster (IBSA Institut Biochimique S.A.) or 
matched placebo, topically applied once a day for 4 weeks 
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on the most painful area of the lateral epicondyle. Patients 
renewed the plaster application in the morning of each day, 
approximately at the same time of the day, and removed 
the plaster in the evening, approximately 12 hours after. An 
elastic loose net was supplied to keep the plaster adhered to 
the skin. However, the use of any kind of occlusive bandage 
over the entire medicated plaster was forbidden. Subjects 
were instructed to take their shower/bath during the treat-
ment-free period, and to carefully dry the to-be-treated skin 
area before any new plaster application. 
During the entire study period, NSAIDs, local (intra-ten-
dinous or intra-articular injections) or systemic corticoste-
roids, physiotherapy, electro-medical Tecar therapy, laser 
therapy, iontophoresis, manipulation and acupuncture were 
not permitted. 
The primary efficacy endpoint of the study was the pain 
decrease from baseline to Day 28, as scored by the patient 
using a 0-100 mm VAS (0 = no pain, 100 = worst imaginable 
pain) while performing the standardized movement. The 
secondary efficacy endpoints were: pain decrease at Day 7, 
14 and 21; patient-rated tennis elbow evaluation (PRTEE) 
score;14 sum of pain intensity difference (SPID) defined 
as the sum of differences from baseline to any follow-
up visit; morning, evening and mean daily pain based on 
daily patients’ diary of VAS; patient’s self-perceived level of 
improvement based on a 6-points Likert scale (complete-
ly recovered/much improved/improved/no change/worse/
much worse); rate of success (i.e. completely recovered or 
much improved as defined above) at Day 28; use of rescue 
medication, i.e. paracetamol (dose and rate of users).
Safety parameters were: treatment-emergent adverse events 
(TEAEs) and vital signs (heart rate and blood pressure). 
Skin irritation at the plaster application site was scored 
using a 5-point scale: 0=none, i.e. no evidence of irritation; 
1=mild, i.e. presence of minimal erythema, barely percepti-
ble; 2=moderate, i.e. presence of definite erythema, readi-
ly visible or minimal oedema or minimal papular response; 
3=severe, i.e. presence of one or more of the following signs: 
erythema and papules; definite oedema; erythema, oedema, 
and papules; vesicular eruption; 4=very severe, i.e. presence 
of a strong reaction spreading beyond the application site. 
Presence of skin atrophy at the plaster application site was 
assessed by the investigator at least 20 minutes after the plas-
ter removal using a 5-point scale: 0=no change from normal 
skin; 1=slight increase in skin transparency; 2=moderate 
increase in skin transparency and presence of telangiectasia 
just visible with the naked eye; 3=marked skin thinning and 
increase in transparency, with marked telangiectasia; 4=very 
severe thinning of the skin with vasculature appearing to 
be directly under the surface and very severe telangiecta-
sia with large blunt vessels. The study protocol, the patient 
information leaflet and the informed consent document 
were first submitted to and approved by the reference Inde-
pendent Ethic Committee (IEC) of the coordinating centre 
(Unit of Orthopaedics and Traumatology, General Hospital, 
Legnano - MI, Italy) and were then approved by the refer-
ence IEC of each investigational study site prior to the start 
of any study-related procedure. Patients gave their written 
informed consent to study participation. The study met the 
ethical standards of the Muscle, Ligaments and Tendons 
Journal (15). 
The sample size calculation was based on the results of the 
previous phase II study (Frizziero et al, 2016) (13) in which 
the mean difference observed between BMV and place-
bo in pain reduction at 28 days ranged between 16 and 19 
mm depending on the plaster dose regimen and applica-
tion duration (12 or 24 hours daily). In this study, it was 
hypothesized that a sample size of 86 patients in each group 
would have had a 90% power to detect a difference of 15 
mm between BMV and placebo in mean pain reduction at 
Day 28, assuming a standard deviation (SD) equal to 30 mm 
and using a two group t-test with a 0.05 two-sided signifi-
cance level. 
All statistical analyses and data processing were performed 
using SAS® Software release 9.2 for Windows (SAS Insti-
tute, Inc., Cary, North Carolina, USA). All efficacy variables 
were analysed in the intent-to-treat (ITT) population, which 
included all randomised patients. Analysis of the primary 
efficacy endpoint was repeated in the per-protocol (PP) 
population, which included all ITT patients who complet-
ed the treatment without any major protocol deviation and 
those patients who interrupted prematurely the treatment 
due to specific reasons such as lack of efficacy of study drug 
or adverse drug reactions (ADRs). The analysis of safety 
endpoints was performed in the safety population, which 
included all randomized patients who received at least one 
dose of study medication.
At each post-baseline visit, mean and SD of the change from 
baseline in pain VAS score were calculated with the rela-
tive 95% confidence interval (CI). The comparison between 
groups was performed with an analysis of covariance 
(ANCOVA) model with change from baseline as dependent 
variable, treatment and centre as fixed effects, and baseline 
value as covariate. The same ANCOVA model was used 
for the comparison between groups in SPID and PRTEE 
questionnaires scores. The comparison between treatment 
groups in weekly means of diary pain values (daily, morn-
ing and evening) was performed using a mixed model for 
repeated measures (MMRM) with the change from baseline 
at each inter-visit period as dependent variable, treatment 
and treatment*visit interaction as fixed effects and baseline, 
centre and baseline*visit interaction as covariates. 
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A Chi-square test was used for the 
comparison between groups of 
proportion of successes, incidence of 
adverse events, and severity scores of 
skin irritation and skin atrophy. The 
comparison between groups in total 
dose and mean daily dose of rescue 
medication was performed using an 
analysis of variance (ANOVA) model.
The last observation carried forward 
(LOCF) method was applied for miss-
ing values in all analyses that required 
complete patient data (ANCOVA 
models).
RESULTS
A total of 200 patients were screened 
in 16 Orthopaedic sites in Italy and 199 
were randomized to the assigned treat-
ment: 101 patients were randomised to 
receive BMV and 98 were randomised 
to placebo. One patient was a screen-
ing failure. Eight (7.9%) patients in the 
BMV group and 8 (8.2%) patients in 
the placebo group prematurely discon-
tinued the study; consent withdrawal 
was the primary reason for discontinu-
ation (7 and 3 patients, respectively in 
the two groups).
Fifteen patients (8 in the BMV group 
and 7 in the placebo group) did not 
complete the treatment period or had 
major deviation from the protocol and 
were therefore excluded from the PP 
population (93 and 91 patients, respec-
tively in the two groups).
Demographic and characteristics at 
baseline, including pain intensity and 
PRTEE scores, were comparable in 
the two groups (table I) except for a 
longer time since first symptoms in the 
BMV group compared to the placebo 
group.
Figure 1 shows the results of pain VAS 
in the ITT population. The decrease 
from baseline in mean VAS score was 
higher in the BMV group than in the 
placebo group at any post-baseline 
time point. The difference between 
adjusted mean changes from baseline 








  Mean (SD) 49.4 (11.0) 49.9 (9.6) 49.7 (10.3)
  Median (range) 50.0 (23-77) 50.5 (23-76) 50.0 (23-77)
Sex, N (%)
  Male 52 (51.5%) 53 (54.1%) 105 (52.8%)
  Female 49 (48.5%) 45 (45.9%) 94 (47.2%)
Ethnic origin, N (%)
  Caucasian 100 (99.0%) 97 (99.0%) 197 (99.0%)
  Asiatic 1 (1.0%) 1 (1.0%) 2 (1.0%)
BMI (kg/m2)
  Mean (SD) 24.99 (3.503) 25.00 (3.701) 24.99 (3.593)
  Median (range) 24.93 (18.71-34.29) 24.82 (17.57-40.56) 24.91 (17.57-40.56)
Affected elbow, N (%)
  Left 31 (30.7%) 35 (35.7%) 66 (33.2%)
  Right 70 (69.3%) 63 (64.3%) 133 (66.8%)
Duration of tendinopathy (weeks)
  Mean (SD) 62.9 (93.8) 42.0 (54.7)* 52.7 (77.7)
  Median (range) 28.0 (12-521) 24.0 (13-349) 25.5 (12-521)
Pain evaluation (VAS)
  Mean (SD) 70.1 (10.7) 67.9 (11.1) 69.0 (10.9)
  Median (range) 69.0 (52-100) 67.0 (50-98) 68.0 (50-100)
PRTEE total score
  Mean (SD) 58.2 (15.9) 59.0 (15.9) 58.6 (15.9)
  Median (range) 58.5 (24-100) 61.0 (18-87) 59.0 (18-100)
PRTEE Pain score
  Mean (SD) 29.8 (7.9) 29.3 (8.0) 29.5 (7.9)
  Median (range) 29.0 (13-50) 30.0 (9-44) 30.0 (9-50)
PRTEE Functional Disability score
  Mean (SD) 28.4 (9.1) 29.7 (8.8) 29.0 (9.0)
  Median (range) 29.0 (8-50) 30.8 (9-47) 29.5 (8-50)
N = number of patients
*One patient had missing value
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*p<0.05 between groups
Figure 1. Results of pain VAS. Data are mean changes from baseline with SD in bars.
*p<0.05 between groups
Figure 2. Results of PRTEE total score, pain score and functional disability score. 
Data are mean changes from baseline to Day 28, with SD in bars.
to Day 28 in the BMV (-32.47 mm; 95% CI: -37.96 to -26.98 mm) and in the 
placebo group (-23.90 mm; 95% CI: -29.47 to -18.33 mm) was -8.57 mm (95% 
CI: -16.19 to -0.95 mm) and was statistically significant (p=0.028), in favour of 
BMV. The comparison between groups at the other time points showed that the 
difference between adjusted means of BMV and placebo at Day 21 was -8.00 
mm (95% CI: -14.80 to -1.20 mm) and was statistically significant (p=0.021), in 
favour of BMV, whereas the difference between groups at Day 7 and Day 14 was 
not statistically significant. In the PP population, the difference between adjust-
ed means of BMV -33.68 mm (95% CI: -39.28 to -28.08 mm) and placebo -23.24 
mm (95% CI: -28.94 to -17.55 mm) 
was -10.44 mm (95% CI: -18.22 to 
-2.65 mm) and was statistically signifi-
cant (p=0.009), in favour of BMV. 
The mean decrease in PRTEE total, 
pain and functional disability scores 
from baseline to Day 28 were higher 
in the BMV group than in the place-
bo group (figure 2). The difference 
between BMV and placebo in adjust-
ed mean changes from baseline to Day 
28 was -5.689 mm (95% CI: -11.73 to 
0.35 mm; p=0.065) for PRTEE total 
score, -3.085 mm (95% CI: -6.13 to 
-0.04 mm; p=0.047) for PRTEE pain 
score and -2.48 mm (95% CI: -5.63 to 
0.67 mm; p=0.122) for PRTEE func-
tional disability score.
The adjusted mean SPID was 789.37 
mm (95% CI: 652.02 to 926.02 m) in 
the BMV group and 613.39 mm (95% 
CI: 474.06 to 752.72 mm) in the place-
bo group. The difference between 
adjusted means of BMV and placebo 
was 175.98 mm (95% CI: -14.70 to 
366.65 mm; p=0.070). 
The results of mean daily pain, morn-
ing pain and evening pain (figure 3), 
as measured by patients on the daily 
diary, showed higher decreases from 
baseline in the BMV group than in 
the placebo group at any post-baseline 
time interval. Statistically significant 
differences between groups, in favour 
of the BMV group, were observed at 
Day 15-21 (p=0.013) and Day 22-28 
(p= 0.014) for mean daily pain, Day 
8-14 (p=0.043), Day 15-21 (p=0.008) 
and Day 22-28 (p=0.008) for morning 
pain, and Day 15-21 (p=0.021) and 
Day 22-28 (p=0.025) for evening pain, 
as well as in the overall study period 
for mean daily pain, morning pain and 
evening pain.
A better perception of level of 
improvement was reported in patients 
in the BMV group compared to those 
in the placebo group. At Day 28, 
rates were completely recovered in 8 
(7.9%) patients, much improved in 
29 (28.7%), improved in 29 (28.7%), 
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*p<0.05, **p<0.01 between groups
Figure 3. Results of weekly means of daily pain, morning pain and evening pain. 
Data are mean values with SD in bars.
no change in 25 (24.8%) and wors-
ened in 3 (3.0%) patients in the BMV 
group, and were completely recov-
ered in 5 (5.1%) patients, much 
improved in 22 (22.4%), improved in 
25 (25.5%), no change in 35 (35.7%) 
and worsened in 3 (3.1%) patients 
in the placebo group. Success at 
end of treatment was reported by 37 
(36.6%) patients in the BMV group 
and 27 (27.6%) in the placebo group 
(p=0.183 between groups).
Thirty-one (30.7%) patients in the 
BMV group and 31 (31.6%) in the 
placebo group used rescue medica-
tion during the study. The mean (± 
SD) total number of used tablets of 
rescue medication was 2.50 ± 6.27 in 
the BMV group and 3.38 ± 11.06 in 
the placebo group (p=0.488 between 
groups) and the mean (± SD) daily 
number of used tablets of rescue 
medication was 0.09 ± 0.21 and 0.11 
± 0.37, respectively in the two groups 
(p=0.499 between groups).
TEAEs were reported in 17 (16.8%) 
patients in the BMV group and in 16 
(16.3%) patients in the placebo group. 
None was serious, and ADRs (i.e. treat-
ment-related TEAEs) were reported 
in 4 (4.0%) and 3 (3.1%) patients, 
respectively in the two groups (table 
II). Local adverse effects at the site 
of plaster application were the most 
common ADRs. One patient in the 
BMV group (palpitation) and 2 in the 
placebo group (hypertension in one 
patient and application site erythema 
and pruritus in the other one) discon-
tinued the study due to adverse events.
Table III shows the results of skin 
irritation and skin atrophy in the two 
groups. There was no evidence of skin 
irritation or skin atrophy following 
treatment with BMV. The skin irrita-
tion score was equal to 0 (none, i.e. 
no evidence of irritation) in the vast 
majority (> 90%) of patients in both 
groups at any post-baseline time point, 
as well as the vast majority (> 90%) 
of patients in both groups reported a 
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N (%) No. of ADRs N (%) No. of ADRs
Any ADR 4 (4.0%) 7 3 (3.1%) 4
  Cardiac disorders 1 (1.0%) 2 0 (0.0%) 0
     Palpitations 1 (1.0%) 1 0 (0.0%) 0
     Tachycardia 1 (1.0%) 1 0 (0.0%) 0
  Gastrointestinal disorders 1 (1.0%) 1 0 (0.0%) 0
     Nausea 1 (1.0%) 1 0 (0.0%) 0
General disorders 
and administration site conditions 2 (2.0%) 3 2 (2.0%) 3
     Application site atrophy 1 (1.0%) 1 1 (1.0%) 1
     Application site erythema 1 (1.0%) 1 1 (1.0%) 1
     Application site irritation 1 (1.0%) 1 0 (0.0%) 0
     Application site pruritus 0 (0.0%) 0 1 (1.0%) 1
  Psychiatric disorders 1 (1.0%) 1 0 (0.0%) 0
     Mood swings 1 (1.0%) 1 0 (0.0%) 0
  Vascular disorders 0 (0.0%) 0 1 (1.0%) 1
     Hypertension 0 (0.0%) 0 1 (1.0%) 1
skin atrophy score equal to 0 (no change from normal skin) 
at any post-baseline time point. There were no statistically 
significant differences between groups for both skin irrita-
tion and skin atrophy.
In both groups, there were no important changes from base-
line in heart rate and blood pressure. 
DISCUSSION
The results of this study have shown that treatment with 
BMV 2.25 mg medicated plaster in patients with LET 
was associated with a significantly greater improvement of 
VAS for pain from baseline to Day 28 (primary endpoint) 
compared to matched placebo. The result was consistent 
in both the ITT and the PP populations. The pain reduc-
tion at Day 21 was also significantly higher in the BMV 
group than in the placebo group, whereas the difference 
between groups in pain reduction at Day 7 and Day 14 was 
not statistically significant, despite the higher pain decreas-
es in the BMV group than in the placebo group. Data of 
pain daily measured by patients confirmed the findings from 
measurement at the clinics. The SPID during the 4-week 
treatment period was also higher (although not significant-
ly) in the BMV group than in the placebo group. Moreover, 
treatment with BMV was associated with higher decreas-
es in mean PRTEE total score, pain score and functional 
disability score from baseline to Day 28 compared to place-
bo, and a statistically significant difference between groups 
was observed for PRTEE pain score. A better perception 
of level of improvement was reported at Day 21 and Day 
28 in patients in the BMV group as compared to placebo 
recipients. At the end of treatment (Day 28), more patient 
(although not significantly) in the BMV group than in the 
placebo group achieved a complete recovery or a significant 
improvement, as compared to baseline. The use of rescue 
paracetamol was very limited and similar in the two groups 
and therefore had no impact on results. 
Compared with findings observed with the same BMV 
regimen used in the previous phase II study,13 there was a 
lower pain reduction with BMV, however not compromis-
ing the clinically and statistically significant superiority of 
BMV over placebo. The longer mean duration of tendinop-
athy in the BMV arm compared to placebo (62.9 and 42.0 
months, respectively) and to that observed in the same arm 
in the phase II study (49.4 months) suggests that a signifi-
cant proportion of patients in the BMV arm might have had 
a long-lasting chronic form of tendinopathy, in which corti-
costeroids have limited effects (16). 
Consistently with findings of the previous study (13), BMV 
was as well tolerated as placebo in terms of adverse events 
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Table III. Results of skin irritation and skin atrophy in the two groups (safety population).
Skin irritation
Day 7 Day 14  Day 21 Day 28
BMV (N=101)
  N 97 94 94 94
  Mean (SD) 0.0 (0.1) 0.0 (0.0) 0.0 (0.1) 0.0 (0.1)
  Median (range) 0.0 (0-1) 0.0 (0-0) 0.0 (0-1) 0.0 (0-1)
  Score distribution, N (%)
   None (0) 96 (95.0%) 94 (93.1%) 93 (92.1%) 93 (92.1%)
   Mild (1) 1 (1.0%) - 1 (1.0%) 1 (1.0%)
   Severe (3) - - - -
Placebo (N=98)
  N 96 95 92 90
  Mean (SD) 0.0 (0.3) 0.0 (0.1) 0.0 (0.1) 0.0 (0.0)
  Median (range) 0.0 (0-3) 0.0 (0-1) 0.0 (0-1) 0.0 (0-0)
 Score distribution, N (%)
   None (0) 94 (95.9%) 94 (95.9%) 90 (91.8%) 90 (91.8%)
   Mild (1) 1 (1.0%) 1 (1.0%) 2 (2.0%) -
   Severe (3) 1 (1.0%) - - -
Skin atrophy
Day 7 Day 14  Day 21 Day 28
BMV (N=101)
  N 98 95 94 94
  Mean (SD) 0.0 (0.0) 0.0 (0.1) 0.0 (0.1) 0.0 (0.1)
  Median (range) 0.0 (0-0) 0.0 (0-1) 0.0 (0-1) 0.0 (0-1)
  Score distribution, N (%)
   No change (0) 98 (97.0%) 94 (93.1%) 93 (92.1%) 93 (92.1%)
   Slight (1) - 1 (1.0%) 1 (1.0%) 1 (1.0%)
Placebo (N=98)
  N 97 95 92 90
  Mean (SD) 0.0 (0.1) 0.0 (0.1) 0.0 (0.1) 0.0 (0.1)
  Median (range) 0.0 (0-1) 0.0 (0-1) 0.0 (0-1) 0.0 (0-1)
 Score distribution, N (%)
   No change (0) 95 (96.9%) 94 (95.9%) 91 (92.9%) 89 (90.8%)
   Slight (1) 2 (2.0%) 1 (1.0%) 1 (1.0%) 1 (1.0%)
N = number of patients
and ≤ 4% of patients in both groups had treatment-relat-
ed adverse TEAEs. Evidence of minimal erythema or slight 
increase in skin transparency at plaster application site was 
only occasionally reported. Only one case of mild erythema 
was reported in the BMV group, and more severe skin irrita-
tion was only reported in one placebo-treated patient.
Treatment of LET is mainly based on conservative measures 
such as physical therapy (17). Corticosteroid injections 
given in addition to physiotherapy are effective for short-
term pain control but have not demonstrated long-term 
benefit (18). There is also limited evidence on the effects 
of non-steroidal anti-inflammatory drugs (NSAIDs) in the 
treatment of pain in elbow tendinopathy (19). Furthermore, 
there is some evidence on the efficacy of topical formula-
tions of corticosteroids or NSAIDs when used in combina-
tion with iontophoresis and phonophoresis, two methods of 
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driving topically applied substances across tissues by utili-
zation of electric current or ultrasound, respectively (5). 
Overall, the existing literature does not provide conclusive 
evidence that there is one preferred method of non-surgical 
treatment for this condition (20). 
Compared to marketed dermatological formulations for 
topical use, such as creams/ointments, BMV medicated 
plaster may offer many advantages: it is formulated in a 
highly-standardised, fixed-dose plaster form, also represent-
ing a user-friendly delivery system for self-medication. The 
occlusive nature of the medicated plaster makes it possible 
to improve the steroid absorption in the site of action and 
possibly enhance its penetration in target connective tissues. 
Furthermore, the BMV medicated plaster may increase the 
patient adherence to treatment by reducing the sensation of 
greasy skin and avoiding its removal by clothes and dress-
ings spots, typical of cream, gels and unguents, while avoid-
ing at the same time the dispersion of active substance on 
unaffected areas, with potential advantages in terms of local 
safety. Finally, the use of BMV medicated plaster is less cost-
ly and time consuming compared to physical therapy, alone 
or associated with modalities such as iontophoresis, ultra-
sound, phonophoresis, or low-level laser treatment.
Despite the clear benefits observed with BMV 2.25 mg 
medicated plaster, this study has some limitations and 
some unanswered questions might be the matter for future 
research. Neither the previous phase II study (13) nor this 
study has included an actively-treated control group and 
therefore it is not possible to compare the extent of the 
effects of BMV medicated plaster with other alternative 
therapies. Moreover, the lack of a comparative alternative 
treatment has not allowed a reliable evaluation of the facili-
ty and convenience of use of the BMV formulation. During 
the choice of the study design, it was considered that the 
use of a comparative active arm would have compromised 
the blindness of the study, which is important to strength-
en outcomes in variables subjectively measured by patients. 
Furthermore, the period of observation lasted with the end 
of treatment, without any follow-up period aimed at inves-
tigating whether the effects of BMV medicated plaster may 
be extended beyond the end of treatment and its efficacy in 
preventing symptoms relapse.  
In conclusion, findings of this placebo-controlled study have 
provided confirmatory evidence of the efficacy of a 28-day 
treatment with BMV 2.25 mg medicated plaster applied 
12 hours/day as pain reliever in patients with LET. BMV 
medicated plaster was as well tolerated as placebo. Further 
comparative trials would be helpful to better understand 
the advantages of BMV 2.25 mg medicated plaster over 
standard therapies in terms of convenience of use, duration 
of effects and improved compliance. 
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